Merck and Pfizer have announced a second accelerated approval in the US for Bavencio in less than two months, in this instance for certain patients with metastatic urothelial carcinoma.
Drugdu Technology Co., Ltd., a developer of the leading global pharmaceutical and medical device B2B platform Drugdu.com (Ddu), today announced that it will attend Hospitalar 2017 from May 16 to 19 in Sao Paulo, Brazil. Drugdu.com will showcase products of premium members and deliver innovative solutions, which are attractive not only for its users, but for the whole healthcare industry.
GlaxoSmithKline and Innoviva have unveiled data from a second ground-breaking Salford Lung Study (SLS) showing that Relvar Ellipta significantly improved asthma control versus patients’ standard therapy.
WHO is improving transparency and accountability with the launch of a redesigned Programme Budget Web Portal that makes budget and spending information easier to access, use and understand.
Patients with a rare form of leukaemia look set to win routine access to a novel treatment option on the NHS in England and Wales after Amgen’s Blincyto was backed by cost watchdog NICE
Recently, The first face-to-face communication meeting with Ddu high priority members was held by Drugdu.com (Ddu), a global leading pharmaceutical and medical device B2B Online platform. Ddu and the members together discussed the future trend of medical cross-border trade, introduced credit guarantee system, exhibition promotion service and development plan. Ddu also answered questions from members.
The 33rd Korea International Medical& Hospital Equipment Show(KIMES 2017) took place from March 16th to 19th for four days at COEX in Seoul. As an exhibitor, Ddu introduced a special B2B experience to international companies of pharmaceutical and medical device, which won high praise from partners and visitors at home and abroad.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.